Irina Volosko, DO
Glaucoma Specialist · Austin, TXNPI 1023520624
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,676 of the $10,569 with a category attached, or 63.2%. 24 manufacturers reported payments, led by AbbVie at 29.2% of the total.
Across 138 payments — averaging $76.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$2K
- Alcon$1K
- Bausch & Lomb Americas Inc.$579
- NEW World Medical,inc.$418
- Rxsight Inc$377
- plus $3K from 18 others
What the payments were for
- Consulting fees$2,20021%
- Travel & lodging$1,53114%
- Food & beverage$6,67663%
- Education$180%
- Entertainment$1441%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 25 | $3,089 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 14 | $1,965 |
| Alcon | 27 | $1,478 |
| Bausch & Lomb Americas Inc. | 22 | $579 |
| NEW World Medical,inc. | 6 | $418 |
| Rxsight Inc | 5 | $377 |
| Sight Sciences, Inc. | 5 | $325 |
| Glaukos Corporation | 3 | $316 |
| Biotissue Holdings Inc. | 5 | $312 |
| Regeneron | 2 | $300 |
| Amgen | 5 | $269 |
| Apellis Pharmaceuticals, Inc. | 2 | $243 |
| Sun Pharmaceutical Industries Inc. | 2 | $162 |
| Optos, Inc. | 1 | $144 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $132 |
| Astellas Pharma US Inc | 1 | $130 |
| Mallinckrodt Enterprises LLC | 1 | $105 |
| Tarsus Pharmaceuticals, Inc. | 2 | $60 |
| Thea Pharma Inc. | 2 | $46 |
| Novartis | 2 | $38 |
| Oyster Point Pharma, Inc. | 1 | $26 |
| Tearlab Corp | 1 | $22 |
| Omeros Corporation | 1 | $19 |
| Harrow Eye, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- STELLARIS PC$1,643
- CRYSTALENS$1,643
- AKREOS AO$1,643
- ENVISTA$1,643
- TRULIGN TORIC$1,643
- XEN GLAUCOMA TREATMENT SYSTEM$1,341
- DURYSTA$1,100
- Centurion$392
- EYLEA HD$300
- iDoseTR$293
- PANORAMIC OPHTHALMOSCOPE$289
- OCT OPHTHALMOSCOPE$289
- OMNI(R) SURGICAL SYSTEM (US)$276
- Syfovre$243
- TEPEZZA$222
- Clareon$222
- Kahook Dual Blade$200
- Clearpath$200
- Ahmed Glaucoma Valve$200
- Streamline$200
How this compares
$10,569 in reported general payments places this provider in the 80th percentile of 31 glaucoma specialist providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RocklatanNetarsudil Mesylat/Latanoprost | 107 | $53,671 |
| RestasisCyclosporine | 16 | $22,900 |
| LumiganBimatoprost | 49 | $22,796 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 40 | $14,094 |
| VyzultaLatanoprostene Bunod | 23 | $11,205 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 61 | $10,635 |
| Brimonidine Tartrate | 137 | $6,830 |
| Latanoprost | 437 | $5,202 |
| CombiganBrimonidine Tartrate/Timolol | 17 | $4,635 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 150 | $2,408 |
| Timolol Maleate | 143 | $1,694 |
| Pilocarpine Hcl | 32 | $1,496 |
| Dorzolamide Hcl | 71 | $1,445 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 13 | $1,304 |
| Prednisolone Acetate | 25 | $835 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $3,089 | $50,33082 claims |
| AlconSimbrinza | $1,478 | $14,09440 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $579 | $11,20523 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 31 glaucoma specialist providers in Texas.
Other glaucoma specialist in Austin
- Amenze OriaifoAustin$18K
- Robert MarquisAustin$3K
- Shivani KamatDallas$164K
- Robert FeldmanHouston$31K
- David LeeHouston$17K
- Nicholas GurneyFt Worth$13K
- Patrick WuHouston$11K
- Logan VincentTyler$5K
- Thao ThachGarland$4K
- Elza RachidHouston$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.